Latest Conference Coverage

Jeremy Payne, MD, PhD: The Need to Improve Telestroke Care

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed how data from the TELECAST trial impact existing literature and the areas of improvement for the current use of telemedicine for stroke.

Fenfluramine-Reduced Seizure Frequency in Dravet Improves Executive Function

Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.

Where Do Ubrogepant and the Gepant Class Fit in Migraine Care?

The director of the Montefiore Headache Center discussed recent study findings on ubrogepant and offered insight into the possible future of the gepant class in migraine.

Bhooma Aravamuthan, MD, DPhil: Improving Neurologists' Focus on Cerebral Palsy

The assistant professor of neurology at the University of Washington in St. Louis detailed the ­­factors that may contribute to these inconsistencies in cerebral palsy diagnosis and what role neurologists should play.

Ponesimod Displays Superiority in Relapsing MS Treatment

Janssen’s S1P receptor modulator ponesimod showed its superiority to teriflunomide on annualized relapse rates, fatigue symptoms, MRI activity, brain atrophy, and NEDA-3 in patients with relapsing multiple sclerosis.

Galcanezumab Has Significant Impact for Patients With Refractory Migraine

The FDA-approved anti-CGRP therapy from Eli Lilly demonstrated a significant ability to decrease monthly migraine days in patients who did not respond to previous medications.

Jeffrey Cohen, MD: Ofatumumab's Potential Role in MS Care

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the wide variety of clinical benefits observed with ofatumumab treatment and how it fits into the MS care landscape.

Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS

Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.

Lasmiditan Improves Migraine-Related Disability

The FDA-approved migraine therapy lasmiditan showed long-term efficacy and had similar change in Migraine Disability Assessment total score in both 100-mg and 200-mg doses.

Bhooma Aravamuthan, MD, DPhil: Inconsistencies in Diagnosing Cerebral Palsy

The assistant professor of neurology at the University of Washington in St. Louis discussed a study she and colleagues conducted which revealed significant differences between practitioners in diagnosing cerebral palsy.

Ubrogepant More Effective in Mild Pain Migraine Attacks

Allergan’s oral CGRP antagonist showed a higher likelihood of freedom from pain and associated symptoms during mild headaches for patients with migraine compared to attacks of moderate to severe severity.

Erenumab Shows Long-Term Success in Migraine Treatment

The anti-CGRP agent showed sustained benefit in reducing migraine frequency as well as good safety over 4 or more years of treatment in a cohort of more than 200 patients.

Jeffrey Cohen, MD: The Success of Ofatumumab in Relapsing MS

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the findings of a new pooled-data analysis of ofatumumab from the phase 3 ASCLEPIOS I and II trials.

Risdiplam Demonstrates Significant Motor Milestones in Infants with Type 1 SMA

In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified.

Eptinezumab Improves Consecutive Migraine-Free Days, Shortens Migraine Duration

These data on the preventive migraine treatment confirmed findings from previous studies, with eptinezumab not only reducing total migraine days, but elongating the duration of consecutive migraine-free days.

Epidiolex Has Safe, Consistent Profile Over Long-Term in Tuberous Sclerosis Complex

Treatment with CBD resulted in a significant number of patients with TSC reporting being “much” or “very much” improved on the Subject/Caregiver Global Impression of Change.

M. Scott Perry, MD: Clinical Experience With Fenfluramine in Dravet Syndrome

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed his experience with Zogenix’s investigational Dravet syndrome treatment in clinical trials and in the Expanded Access Program.

Optimizing Acute Migraine Care Improves Quality of Life and Reduces Disability

Data from the OVERCOME study of more than 20,000 respondents suggest that those whose acute migraine treatment was optimized according to the mTOQ had less disability and better quality of life.

Ofatumumab Displays Superiority to Teriflunomide in Relapsing MS

Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.

M. Scott Perry, MD: Real-World Fenfluramine Data in Dravet Syndrome

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.

Rimegepant Shows Early Efficacy in Acute Migraine Treatment

Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.

Real-World Dravet Syndrome Data Suggest Fenfluramine Provides Benefit

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.

Post-Hoc Analysis Suggests Eptinezumab Effective for Migraine at Initial Dosing

Data confirmed the prior results of the PROMISE-1 and PROMISE-2 studies, indicating the preventive effect on migraine with eptinezumab begins as early as day 1 post-infusion.

BTK Inhibitor SAR442168 Meets Multiple Sclerosis End Points in Phase 2b

The drug's impact on neuroinflammation and neurodegeneration in the brain and spinal cord are currently being explored.

Siponimod Shows Long-Term Benefit for Secondary Progressive MS

Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.

Erenumab Improves Daily Functioning and Quality of Life

The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine.

Perampanel May Improve Insomnia in Patients With Epilepsy and Anxiety

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

Mary Rensel, MD: Transitioning to Shared Medical Appointments

The director of Pediatric MS and Wellness programming at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine discussed the harsh realities of patients adopting a new treatment method.

Le Hua, MD: Siponimod in Secondary Progressive Multiple Sclerosis

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.

Le Hua, MD: Subanalysis of the EXPAND Study of Siponimod in SPMS

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.